抗磷脂抗体不能预测21世纪SLE患者的损伤:来自Lupus-Cruces队列的观察性研究
该研究比较了2000年前后诊断的SLE患者中抗磷脂抗体(aPL)对整体及心血管损伤的影响。结果发现,2000年前诊断的aPL阳性患者损伤累积显著增加,而2000年后诊断者无此差异,可能与羟氯喹(HCQ)广泛使用及更好的血栓预防有关。
要点
- 2000年前诊断的aPL阳性SLE患者整体损伤风险升高(HR 1.98),心血管损伤风险显著升高(HR 9.3)。
- 2000年后诊断的aPL阳性与阴性患者损伤累积无显著差异。
- 高血压、狼疮抗凝物(LA)及HCQ使用时长是aPL阳性患者血管损伤的独立预测因素。
核心结论
- 近年来aPL对SLE患者损伤累积的影响已减弱,可能与HCQ广泛使用及更好的血栓预防有关。
研究设计与样本
- 比较两个亚队列中aPL阳性与阴性患者的SLICC-ACR损伤指数评分及整体和心血管无损伤生存率。
主要发现
- 2000年前诊断亚队列中,aPL阳性患者较阴性患者累积更多损伤;调整后整体损伤HR 1.98(95%CI 1.24, 3.14),心血管损伤HR 9.3(95%CI 3.24, 26.92)。
- 2000年后诊断亚队列中,aPL阳性与阴性患者损伤无差异。
- 全部aPL阳性患者联合分析中,高血压(HR=4.64,95%CI 1.33, 16.19)、LA(HR=3.85,95%CI 1.1, 13.41)及HCQ使用月数(HR=0.97,95%CI 0.95, 0.99)是血管损伤的独立预测因素。
临床怎么用
- 对aPL阳性SLE患者应重视控制高血压并规律使用HCQ,以降低血管损伤风险。
- 2000年后诊断的aPL阳性患者损伤风险未显著增加,提示现代管理策略可能改善预后。
局限性
- 本研究为观察性队列研究,不能确立因果关系。
- 两个亚队列在治疗变量上存在差异,可能影响结果解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the influence of aPLs on global and cardiovascular damage in patients with SLE diagnosed before and after the year 2000. METHODS: Two hundred and eighty-six patients from the Lupus-Cruces cohort with a minimum follow-up of 5 years were divided into two subcohorts according to the date of diagnosis, before 2000 (less than 2000) and from 2000 on (2000 or more). We compared the mean Systemic Lupus Erythematosus International Collaborating Clinics-American College of Rheumatology (SLICC-ACR) Damage Index score and global and cardiovascular damage-free survival rates in the presence or absence of aPL in both subcohorts. Variables potentially modulating damage among aPL-positive patients were analysed. RESULTS: The subcohorts were comparable for demographic and lupus-related variables except for treatment variables: the 2000 or more subcohort received lower doses of prednisone and more HCQ, low-dose aspirin, statins, immunosuppressive agents and vitamin D. aPL-positive patients in the less than 2000, but not in the 2000 or more subcohort, accrued more damage compared with aPL-negative patients. In the less than 2000 subcohort, the adjusted hazard ratios (HRs) for global and cardiovascular damage in aPL-positive vs aPL-negative patients were 1.98 (95% CI 1.24, 3.14) and 9.3 (95% CI 3.24, 26.92), respectively. No differences in damage were seen between aPL-positive and aPL-negative patients in the 2000 or more subcohort. Hypertension (HR = 4.64, 95% CI 1.33, 16.19), LA (HR = 3.85, 95% CI 1.1, 13.41) and the number of months on HCQ (HR = 0.97, 95% CI 0.95, 0.99) were independent predictors of vascular damage in the combined analysis of all aPL-positive patients. CONCLUSION: The effects of aPL on damage accrual in SLE patients have been reduced over recent years. The widespread use of HCQ and a better thromboprophylaxis are likely causing this change.
引用
- Ugarte A, Garcia de Bustos A, Ruiz-Arruza I, et al. Anti-phospholipid antibodies do not predict damage in SLE patients in the 21st century-an observational study from the Lupus-Cruces cohort. Rheumatology (Oxford). 2021. PMID: 33769455. doi:10.1093/rheumatology/keab307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。